Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Clinical trials

Medical
Regional

FDA Clears Medicus to Advance Prostate Cancer Drug Aimed at Heart-Risk Patients

February 10, 2026February 10, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) has received clearance from the U.S. Food and Drug Administration to proceed with a Phase 2b clinical study of Teverelix, a long-acting …

FDA Clears Medicus to Advance Prostate Cancer Drug Aimed at Heart-Risk Patients Read More

Prelude Therapeutics
Regional

FDA Clears Prelude’s Experimental Cancer Drug, Opening New Path for Blood Disorders

February 8, 2026February 6, 2026 - by Timothy Alexander

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) said the U.S. Food and Drug Administration has cleared its investigational new drug application for PRT12396, allowing the company to begin a …

FDA Clears Prelude’s Experimental Cancer Drug, Opening New Path for Blood Disorders Read More
Frontage Laboratories
Business

Frontage Scales Global Phase I Reach as Patent Cliff Accelerates Drug Trials

February 5, 2026February 4, 2026 - by Timothy Alexander

EXTON, PA — Frontage Laboratories, Inc. announced a major expansion of its early phase clinical research capabilities across the United States and China, positioning the company to meet surging demand …

Frontage Scales Global Phase I Reach as Patent Cliff Accelerates Drug Trials Read More

Aprea Therapeutics
Regional / Research

Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial

February 3, 2026February 2, 2026 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported its first unconfirmed partial response in a Phase 1 study of its experimental cancer drug APR-1051, an early signal the company …

Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial Read More
Aclaris Therapeutics
Research

Experimental Hair-Loss Drug Sparks Rapid Regrowth in Severe Alopecia Study

February 3, 2026February 2, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported striking preclinical results for its experimental oral drug ATI-2138, showing rapid, near-complete, and sustained hair regrowth in a severe mouse model …

Experimental Hair-Loss Drug Sparks Rapid Regrowth in Severe Alopecia Study Read More

Traws Pharma
Regional

Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones

February 2, 2026February 2, 2026 - by Timothy Alexander

NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) said it has completed enrollment in a 90-patient Phase 2 study testing its experimental oral COVID-19 treatment ratutrelvir against PAXLOVID®, reporting early …

Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones Read More
Medical research
Regional

Experimental Pompe Therapy Shows Early Signal Ahead of Key San Diego Reveal

January 31, 2026January 30, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Aro Biotherapeutics said it will present interim clinical data next month from its ongoing Phase 1b trial of ABX1100, an experimental therapy aimed at treating late-onset Pompe …

Experimental Pompe Therapy Shows Early Signal Ahead of Key San Diego Reveal Read More

Suvoda
Regional

Suvoda Bets on Merger, AI to Simplify Clinical Trials and Boost Growth

January 25, 2026January 24, 2026 - by Timothy Alexander

ONSHOHOCKEN, PA — Suvoda said it made significant strides in 2025 toward simplifying the clinical trial experience for patients and research sites, pointing to its merger with Greenphire, expanded product …

Suvoda Bets on Merger, AI to Simplify Clinical Trials and Boost Growth Read More
Dispatch Bio
Regional

Dispatch Bio and CARsgen Strike China Deal to Test New CAR T Approach

January 23, 2026January 21, 2026 - by Timothy Alexander

PHILADELPHIA, PA & SAN FRANCISCO, CA & SHANGHAI, China — Dispatch Bio and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) said they have entered into a clinical collaboration to conduct …

Dispatch Bio and CARsgen Strike China Deal to Test New CAR T Approach Read More
Ocugen
Research

Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy

January 22, 2026January 20, 2026 - by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said preliminary 12-month data from its Phase 2 ArMaDa clinical trial showed meaningful reductions in disease progression for patients with geographic atrophy, a …

Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy Read More

Posts pagination

Previous 1 2 3 4 … 37 Next

Trending News

  • Retail Theft Ring Accused of $7,660 Ulta Store Heist in Wyomissing

  • Police Respond to Fight, Crashes, and Domestic Call in Wyomissing

  • Burglars Break Into Southwest Philly Store, Steal Cash and Electronics

  • Gwynedd Mercy University Launches Three-Year Nursing Degree Program

  • Whitford Road Closure Could Disrupt Chester County Commutes

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Arrested

Retail Theft Ring Accused of $7,660 Ulta Store Heist in Wyomissing

1 hour ago5 hours ago

Police News

Police Respond to Fight, Crashes, and Domestic Call in Wyomissing

2 hours ago6 hours ago

Commercial Burglary, 7012 Elmwood Ave

Burglars Break Into Southwest Philly Store, Steal Cash and Electronics

3 hours ago6 hours ago

Copyright © 2026 MyChesCo.